Nanobiotix S.A.
NBTX · XNASCIK 1760854fmd_1XDSAZR8H1E9WY23R3N6V1HJF9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 14 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 3 | 3 | 3 | 5 | 36 | (7) | 33 |
| Research and development | 21 | 30 | 24 | 30 | 33 | 38 | 41 | 23 |
| Selling, general and administrative | 13 | 19 | 15 | 19 | 18 | 22 | 21 | 20 |
| Operating income | (30) | (47) | (36) | (53) | (47) | (27) | (68) | (11) |
| Interest expense | 1 | 5 | (3) | 1 | 14 | 15 | 7 | 15 |
| Income before taxes | (30) | (51) | (34) | (47) | (57) | (40) | (68) | (24) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (30) | (51) | (34) | (47) | (57) | (40) | (68) | (24) |
| Net income | (30) | (51) | (34) | (47) | (57) | (40) | (68) | (24) |